Abstract
Prostate cancer accounts for around 15% of male deaths in Western Europe and is the second leading cause of cancer death in men after lung cancer. Mounting evidence suggests that prostate cancer deposits exist within a hypoxic environment and this contributes to radio-resistance thus hampering one of the major therapies for this cancer. Recent reports have shown that nitric oxide (NO) donating non-steroidal anti-inflammatory drugs (NSAIDs) reduced tumour hypoxia as well as maintaining a radio-sensitising/therapeutic effect on prostate cancer cells. The aim of this study was to evaluate the impact of hypoxia on the proteome of the prostate and to establish whether NO-NSAID treatment reverted the protein profiles back to their normoxic status. To this end an established hormone insensitive prostate cancer cell line, PC-3, was cultured under hypoxic and normoxic conditions before and following exposure to NO-NSAID in combination with selected other common prostate cancer treatment types. The extracted proteins were analysed by ion mobility-assisted data independent acquisition mass spectrometry (MS), combined with multivariate statistical analyses, to measure hypoxia-induced alterations in the proteome of these cells. The analyses demonstrated that under hypoxic conditions there were well-defined, significantly regulated/differentially expressed proteins primarily involved with structural and binding processes including, for example, TUBB4A, CIRP and PLOD1. Additionally, the exposure of hypoxic cells to NSAID and NO-NSAID agents, resulted in some of these proteins being differentially expressed; for example, both PCNA and HNRNPA1L were down-regulated, corresponding with disruption in the nucleocytoplasmic shuttling process.
Acknowledgments
Craig Dorschel is kindly acknowledged for his assistance with collecting the LC-MS data. FKH and JAR are also grateful to the Prostate Cancer Charity and Ralph Shackman Trust for their support.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organisation(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008;8:967–75.10.1038/nrc2540Search in Google Scholar PubMed PubMed Central
2. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012;33:207–14.10.1016/j.tips.2012.01.005Search in Google Scholar PubMed PubMed Central
3. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int 2010;105:8–13.10.1111/j.1464-410X.2009.08921.xSearch in Google Scholar PubMed
4. Ranasinghe WK, Xiao L, Kovac S, Chang M, Michiels C, Bolton D, et al. The role of hypoxia-inducible factor 1α in determining the properties of castrate-resistant prostate cancers. PLoS One 2013;8:e54251.10.1371/journal.pone.0054251Search in Google Scholar PubMed PubMed Central
5. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol (1985) 2000;88:1474–80.10.1152/jappl.2000.88.4.1474Search in Google Scholar PubMed
6. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer [Internet] 2011;12:9–22.10.1038/nrc3183Search in Google Scholar PubMed PubMed Central
7. Pasanen A, Heikkilä M, Rautavuoma K, Hirsilä M, Kivirikko KI, Myllyharju J. Hypoxia-inducible factor (HIF)-3α is subject to extensive alternative splicing in human tissues and cancer cells and is regulated by HIF-1 but not HIF-2. Int J Biochem Cell Biol 2010;42:1189–200.10.1016/j.biocel.2010.04.008Search in Google Scholar PubMed
8. Shin DH, Li SH, Chun YS, Huang LE, Kim MS, Park JW. CITED2 mediates the paradoxical responses of HIF-1α to proteasome inhibition. Oncogene 2008;27:1939–44.10.1038/sj.onc.1210826Search in Google Scholar PubMed
9. Dewey DL. Effect of oxygen and nitric oxide on the radiosensitivity of human cells in tissue culture. Nature 1960;186:780–2.10.1038/186780a0Search in Google Scholar PubMed
10. Furuta Y, Hunter N, Barkley T, Hall E, Milas L. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res 1988;48:3008–13.Search in Google Scholar
11. Williams JL, Kashfi K, Ouyang N, Del Soldato P, Kopelovich L, Rigas B. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC Min/+) mice. Biochem Biophys Res Commun 2004;313:784–8.10.1016/j.bbrc.2003.12.015Search in Google Scholar PubMed
12. Royle JS, Ross JA, Ansell I, Bollina P, Tulloch DN, Habib FK. Nitric oxide donating nonsteroidal anti-inflammatory drugs induce apoptosis in human prostate cancer cell systems and human prostatic stroma via caspase-3. J Urol 2004;172:338–44.10.1097/01.ju.0000132367.02834.41Search in Google Scholar
13. Tesei A, Ulivi P, Fabbri F, Rosetti M, Leonetti C, Scarsella M, et al. In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. J Transl Med 2005;3:7.10.1186/1479-5876-3-7Search in Google Scholar
14. Stewart GD, Nanda J, Brown DJ, Riddick AC, Ross JA, HabibFK. NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int J Cancer 2009;124:223–32.10.1002/ijc.23934Search in Google Scholar
15. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003;124:600–7.10.1053/gast.2003.50096Search in Google Scholar
16. Umansky V, Schirrmacher V. Nitric oxide-induced apoptosis in tumor cells. Adv Cancer Res 2001;82:107–31.10.1016/S0065-230X(01)82004-2Search in Google Scholar
17. Stewart GD, Nanda J, Katz E, Bowman KJ, Christie JG, BrownDJ, et al. DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions. Biochem Pharmacol 2011;81:203–10.10.1016/j.bcp.2010.09.022Search in Google Scholar PubMed
18. Tanase CP, Codrici E, Popescu ID, Mihai S, Enciu A-M, Necula LG, et al. Prostate cancer proteomics: current trends and future perspectives for biomarker discovery. Oncotarget [Internet] 2017;8:18497–512.10.18632/oncotarget.14501Search in Google Scholar PubMed PubMed Central
19. Rodriguez-Suarez E, Hughes C, Gethings L, Giles K, Wildgoose J, Stapels M, et al. An ion mobility assisted data independent LC-MS strategy for the analysis of complex biological samples [Internet]. Curr Anal Chem 2013;9:199–211.10.2174/1573411011309020006Search in Google Scholar
20. Distler U, Kuharev JJ, Navarro P, Levin Y, Schild HH, Tenzer S. Drift time-specific collision energies enable deep-coverage data-independent acquisition proteomics. Nat Meth [Internet] 2014;11:167–70.10.1038/nmeth.2767Search in Google Scholar PubMed
21. Keam SP, Gulati T, Gamell C, Caramia F, Huang C, Schittenhelm RB, et al. Exploring the oncoproteomic response of human prostate cancer to therapeutic radiation using data-independent acquisition (DIA) mass spectrometry. Prostate 2018;78:563–75.10.1002/pros.23500Search in Google Scholar PubMed
22. Li G-ZZ, Vissers JP, Silva JC, Golick D, Gorenstein MV, Geromanos SJ. Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures. Proteomics [Internet] 2009;9:1696–719.10.1002/pmic.200800564Search in Google Scholar PubMed
23. Silva JC, Gorenstein MV, Li GZ, Vissers JP, Geromanos SJ. Absolute quantification of proteins by LCMSE: a virtue of parallel ms acquisition. Mol Cell Proteomics 2006;5:144–56.10.1074/mcp.M500230-MCP200Search in Google Scholar PubMed
24. Jeanquartier F, Jean-Quartier C, Holzinger A. Integrated web visualizations for protein-protein interaction databases. BMC Bioinformatics 2015;16:195.10.1186/s12859-015-0615-zSearch in Google Scholar PubMed PubMed Central
25. Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. The Reactome Pathway Knowledgebase. Nucleic Acids Res 2018;46:D649–55.10.1093/nar/gkx1132Search in Google Scholar PubMed PubMed Central
26. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009;37:1–13.10.1093/nar/gkn923Search in Google Scholar PubMed PubMed Central
27. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov [Internet] 2012;2:401–4.10.1158/2159-8290.CD-12-0095Search in Google Scholar PubMed PubMed Central
28. Wu G, Dawson E, Duong A, Haw R, Stein L. ReactomeFIViz: a Cytoscape app for pathway and network-based data analysis. F1000Research [Internet] 2014;3:146.10.12688/f1000research.4431.2Search in Google Scholar
29. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res [Internet] 2003;13:2498–504.10.1101/gr.1239303Search in Google Scholar PubMed PubMed Central
30. Mulligan MK, Mozhui K, Prins P, Williams RW. Genenetwork: a toolbox for systems genetics. Methods Mol Biol 2017;1488:75–120.10.1007/978-1-4939-6427-7_4Search in Google Scholar PubMed PubMed Central
31. Zachary S, Danny A, Karl WB, Arthur C, Nicholas F, Harm N, et al. GeneNetwork: framework for web-based genetics. J Open Source Softw 2016;1:1–3.10.21105/joss.00025Search in Google Scholar
32. Vizcaíno JA, Deutsch EW, Wang R, Csordas A, Reisinger F, Ríos D, et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat Biotechnol [Internet] 2014;32:223–6.10.1038/nbt.2839Search in Google Scholar PubMed PubMed Central
33. Ihling A, Ihling CH, Sinz A, Gekle M. Acidosis-induced changes in proteome patterns of the prostate cancer-derived tumor cell line AT-1. J Proteome Res 2015;14:3996–4004.10.1021/acs.jproteome.5b00503Search in Google Scholar PubMed
34. Gallagher IJ, Stewart GD, Nanda J, Riddick AC, Habib FK, Ross JA. Global changes in gene expression in normoxic and hypoxic prostate cancer and the influence of NO-Sulindac. 2019 (manuscript in preparation).Search in Google Scholar
35. Dai Y, Bae K, Siemann DW. Impact of hypoxia on the metastatic potential of human prostate cancer Cells. Int J Radiat Oncol Biol Phys 2011;81:521–8.10.1016/j.ijrobp.2011.04.027Search in Google Scholar PubMed PubMed Central
36. Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, et al. Hypoxic prostate/muscle PO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002;60:634–9.10.1016/S0090-4295(02)01858-7Search in Google Scholar
37. Tamura D, Arao T, Nagai T, Kaneda H, Aomatsu K, Fujita Y, et al. Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells. Cancer Med 2013;2:144–54.10.1002/cam4.68Search in Google Scholar PubMed PubMed Central
38. Binó L, Procházková J, Radaszkiewicz KA, Kučera J, Kudová J, Pacherník J, et al. Hypoxia favors myosin heavy chain beta gene expression in an Hif-1alpha-dependent manner. Oncotarget 2017;8:83684–97.10.18632/oncotarget.19016Search in Google Scholar PubMed PubMed Central
39. Wellmann S, Bührer C, Moderegger E, Zelmer A, Kirschner R, Koehne P, et al. Oxygen-regulated expression of the RNA-binding proteins RBM3 and CIRP by a HIF-1-independent mechanism. J Cell Sci 2004;117:1785–94.10.1242/jcs.01026Search in Google Scholar PubMed
40. Liao Y, Tong L, Tang L, Wu S. The role of cold-inducible RNA binding protein in cell stress response. Int J Cancer [Internet]. 2017;141:2164–73.10.1002/ijc.30833Search in Google Scholar PubMed
41. Thompson LP, Pence L, Pinkas G, Song H, Telugu BP. Placental hypoxia during early pregnancy causes maternal hypertension and placental insufficiency in the hypoxic guinea pig model. Biol Reprod 2016;95:128.10.1095/biolreprod.116.142273Search in Google Scholar PubMed PubMed Central
42. Chang WH, Forde D, Lai AG. Dual prognostic role of 2-oxoglutarate-dependent oxygenases in ten cancer types: implications for cell cycle regulation and cell adhesion maintenance. Cancer Commun 2019;39:23.10.1186/s40880-019-0369-5Search in Google Scholar PubMed PubMed Central
43. Carlucci A, Adornetto A, Scorziello A, Viggiano D, Foca M, Cuomo O, et al. Proteolysis of AKAP121 regulates mitochondrial activity during cellular hypoxia and brain ischaemia. EMBO J 2008;27:1073–84.10.1038/emboj.2008.33Search in Google Scholar PubMed PubMed Central
44. Ma YL, Peng JY, Zhang P, Huang L, Liu WJ, Shen TY, et al. Heterogeneous nuclear ribonucleoprotein A1 is identified as a potential biomarker for colorectal cancer based on differential proteomics technology. J Proteome Res 2009;8:4525–35.10.1021/pr900365eSearch in Google Scholar PubMed
45. Guil S, Long JC, Caceres JF. hnRNP A1 relocalization to the stress granules reflects a role in the stress response. Mol Cell Biol 2006;26:5744–58.10.1128/MCB.00224-06Search in Google Scholar PubMed PubMed Central
46. Ko CC, Chen YJ, Chen CT, Liu YC, Cheng FC, Hsu KC, et al. Chemical proteomics identifies heterogeneous nuclear ribonucleoprotein (hnRNP) A1 as the molecular target of quercetin in its anti-cancer effects in PC-3 cells. J Biol Chem 2014;289:22078–89.10.1074/jbc.M114.553248Search in Google Scholar PubMed PubMed Central
47. Tonry C, Armstrong J, Pennington S. Probing the prostate tumour microenvironment. II: impact of hypoxia on a cell model of prostate cancer progression. Oncotarget 2017;8:15307–37.10.18632/oncotarget.14574Search in Google Scholar PubMed PubMed Central
Supplementary Material
The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2019-0626).
©2020 Walter de Gruyter GmbH, Berlin/Boston
